The Anderson Lab at the University of Virginia

2023

Lessons for the Next Generation of Scientists from the Second Annual Arthur and Sandra Irving Cancer Immunology Symposium. Alvarez-Breckenridge C, Anderson KG, Correia AL, Demehri S, Dinh HQ, Dixon KO, Dunn GP, Evgin L, Goc J, Good Z, Hacohen N, Han P, Hanč P, Hickey J, Kersten K, Liu BC, Buque A, Miao Y, Milner JJ, Pritykin Y, Pucci F, Scharping NE, Sudmeier L, Wang Y, Wieland A, Williams MM. Cancer Immunol Res. 2023 Dec 1;11(12):1571-1577. doi: 10.1158/2326-6066.CIR-23-0522. PMID: 37906619; PMCID: PMC10696930.

Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Anderson K.G., D.A. Braun, A. Buque, S.B. Gitto, B.L. Horton, J.L. Guerriero, B.P. Keenan, T.S. Kim, A.E. Overacre-Delgoffe, M. Ruella, T. Triplett, O. Veeranki, V. Verma, F. Zhang. Journal for ImmunoTherapy of Cancer. 2023 Jun;11(6):e006533. doi: 10.1136/jitc-2022-006533. PMID: 37399356 PMCID: PMC10314654.

2022

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy. Anderson KG, Oda SK, Bates BM, Burnett MG, Rodgers Suarez M, Ruskin SL, Greenberg PD. J Immunother Cancer. 2022 Mar;10(3):e003959. doi: 10.1136/jitc-2021-003959 PubMed PMID: 35264436; PubMed Central PMCID: PMC8915280.

2021

Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease. Morse CB, Voillet V, Bates BM, Chiu EY, Garcia NM, Gottardo R, Greenberg PD, Anderson KG. Gynecol Oncol. 2021 Feb;160(2):427-437. doi: 10.1016/j.ygyno.2020.11.009. Epub 2020 Nov 20. PubMed PMID: 33229044; PubMed Central PMCID: PMC8547140.

2020

Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. Manzo T, Prentice BM, Anderson KG, Raman A, Schalck A, Codreanu GS, Nava Lauson CB, Tiberti S, Raimondi A, Jones MA, Reyzer M, Bates BM, Spraggins JM, Patterson NH, McLean JA, Rai K, Tacchetti C, Tucci S, Wargo JA, Rodighiero S, Clise-Dwyer K, Sherrod SD, Kim M, Navin NE, Caprioli RM, Greenberg PD, Draetta G, Nezi L. J Exp Med. 2020 Aug 3;217(8). doi: 10.1084/jem.20191920. PubMed PMID: 32491160; PubMed Central PMCID: PMC7398173.
Ranked as a 2020 Best of JEM Top 10 Article

A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. Oda SK, Anderson KG, Ravikumar P, Bonson P, Garcia NM, Jenkins CM, Zhuang S, Daman AW, Chiu EY, Bates BM, Greenberg PD. J Exp Med. 2020 Dec 7;217(12). doi: 10.1084/jem.20191166. PubMed PMID: 32860705; PubMed Central PMCID: PMC7953733.

2019

Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer. Anderson KG, Voillet V, Bates BM, Chiu EY, Burnett MG, Garcia NM, Oda SK, Morse CB, Stromnes IM, Drescher CW, Gottardo R, Greenberg PD. Cancer Immunol Res. 2019 Sep;7(9):1412-1425. doi: 10.1158/2326-6066.CIR-19-0258. Epub 2019 Jul 23. PubMed PMID: 31337659; PubMed Central PMCID: PMC6726582.
*Image selected for Cover Art

2017

Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Anderson KG, Stromnes IM, Greenberg PD. Cancer Cell. 2017 Mar 13;31(3):311-325. doi: 10.1016/j.ccell.2017.02.008. Review. PubMed PMID: 28292435; PubMed Central PMCID: PMC5423788.